Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer.
Peroxisome proliferatoreactivated receptors (PPARs) are members of the nuclear hormone receptor superfamily and have been implicated in a variety of physiologic and pathologic processes, such as nutrient metabolism, energy homeostasis, inflammation, and cancer. This article highlights breakthroughs in our understanding of the potential roles of PPARs in inflammatory bowel disease and colorectal cancer. PPARs might hold the key to some of the questions that are pertinent to the pathophysiology of inflammatory diseases and colorectal cancer and could possibly serve as drug targets for new antiinflammatory therapeutic and anticancer agents.
Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Unit 1014; S7.8316A, 6767 Bertner Avenue, Houston, TX 77030, USA.
Dingzhi
D
Wang
Raymond N
RN
DuBois
D000818:Animals; D002908:Chronic Disease; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000517:prevention & control; D018450:Disease Progression; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy / Q000517:prevention & control; D051379:Mice; D047492:Peroxisome Proliferator-Activated Receptors / Q000819:agonists* / Q000235:genetics / Q000378:metabolism*; D051381:Rats
D047492:Peroxisome Proliferator-Activated Receptors